CLINICAL TRIALS PROFILE FOR YUPELRI
✉ Email this page to a colleague
All Clinical Trials for YUPELRI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05165485 ↗ | Phase 4 COPD and Suboptimal Inspiratory Flow Rate | Not yet recruiting | Mylan Inc. | Phase 4 | 2021-12-01 | Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR. |
| NCT05165485 ↗ | Phase 4 COPD and Suboptimal Inspiratory Flow Rate | Not yet recruiting | Theravance Biopharma | Phase 4 | 2021-12-01 | Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR. |
| NCT05207111 ↗ | Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution | Completed | Mylan Pharmaceuticals | Phase 1 | 2021-09-23 | Single-Dose Fasting Bioavailability Study of Revefenacin Inhalation Solution, 175 mcg/3 mL in 24 Healthy Chinese Adult Male and Female Volunteers. This study will evaluate the safety and tolerability of Revefenacin Inhalation Solution in the Chinese population. For the determination of the pharmacokinetic disposition of the formulations, The bioavailability of Revefenacin Inhalation Solution, 175 mcg/3 mL will be assessed through various pharmacokinetic parameters derived from the plasma concentration-time curves of revefenacin and its active metabolite, THRX-195518. |
| NCT05207111 ↗ | Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution | Completed | Mylan Inc. | Phase 1 | 2021-09-23 | Single-Dose Fasting Bioavailability Study of Revefenacin Inhalation Solution, 175 mcg/3 mL in 24 Healthy Chinese Adult Male and Female Volunteers. This study will evaluate the safety and tolerability of Revefenacin Inhalation Solution in the Chinese population. For the determination of the pharmacokinetic disposition of the formulations, The bioavailability of Revefenacin Inhalation Solution, 175 mcg/3 mL will be assessed through various pharmacokinetic parameters derived from the plasma concentration-time curves of revefenacin and its active metabolite, THRX-195518. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for YUPELRI
Condition Name
Clinical Trial Locations for YUPELRI
Trials by Country
Clinical Trial Progress for YUPELRI
Clinical Trial Phase
Clinical Trial Sponsors for YUPELRI
Sponsor Name
